Cost-Utility Analysis of Continuation Versus Discontinuation of First-Line Chemotherapy in Patients With Metastatic Squamous-Cell Esophageal Cancer: Economic Evaluation Alongside the E-DIS Trial

Author(s):

Sophie Marguet ◽

Antoine Adenis ◽

Stéphanie Delaine-Clisant ◽

Nicolas Penel ◽

Julia Bonastre

Keyword(s):

Esophageal Cancer ◽

Economic Evaluation ◽

Squamous Cell ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

First Line ◽

Discontinuation of first-line chemotherapy (CT) after 6 weeks of CT in patients (pts) with metastatic squamous-cell esophageal cancer (MSEC): A randomized phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4002 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4002-4002 ◽

Author(s):

Antoine Adenis ◽

Jaafar Bennouna ◽

Pierre-Luc Etienne ◽

Emilie Bogart ◽

Eric Francois ◽

...

Keyword(s):

Esophageal Cancer ◽

Phase Ii ◽

Squamous Cell ◽

Phase Ii Trial ◽

First Line ◽

Randomized Phase Ii ◽

3612 POSTER Cost Utility Analysis of Modified FLOX as First Line Chemotherapy for Metastatic Colorectal Cancer

European Journal of Cancer ◽

10.1016/s0959-8049(11)71209-6 ◽

2011 ◽

Vol 47 ◽

pp. S262

Author(s):

M.P. Mak ◽

F.H. Souza ◽

D.R. Nebuloni ◽

D.F. Saragiotto ◽

G. Castro ◽

...

Keyword(s):

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

First Line ◽

PCN36 A COST UTILITY ANALYSIS OF FIRST-LINE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF METASTATIC BREAST CANCERAFTERANTHRACYCLINE FAILURE

Value in Health ◽

10.1016/s1098-3015(10)67274-9 ◽

2005 ◽

Vol 8 (6) ◽

pp. A44 ◽

Author(s):

K Le Lay ◽

L Riou França ◽

S Avoinet ◽

N Chemali ◽

R Launois

Keyword(s):

Metastatic Breast ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

First Line ◽

A Cost-Utility Analysis Comparing Two Sequences of Treatment for First-Line Chemotherapy in Metastatic Prostate Cancer (MCRPC): Cabazitaxel Followed by Docetaxel Versus Docetaxel Followed by Cabazitaxel

Value in Health ◽

10.1016/j.jval.2017.08.262 ◽

2017 ◽

Vol 20 (9) ◽

pp. A444 ◽

Author(s):

M Schwager ◽

K Fizazi ◽

N Zaghdoud ◽

R Delva ◽

G Gravis Mescam ◽

...

Keyword(s):

Prostate Cancer ◽

Metastatic Prostate Cancer ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

First Line ◽

Development and Validation of a Predictive Model for Disease Control (Dc) at First Disease Assessment, Among Patients (Pts) with Metastatic Squamous Cell Esophageal Cancer (Mscc) Treated with First-Line Chemotherapy (Ct)

Annals of Oncology ◽

10.1093/annonc/mdu334.58 ◽

2014 ◽

Vol 25 ◽

pp. iv229

Author(s):

N. Kotecki ◽

E. Tresch ◽

N. Penel ◽

S. Hiret ◽

P.L. Etienne ◽

...

Keyword(s):

Esophageal Cancer ◽

Disease Control ◽

Predictive Model ◽

Squamous Cell ◽

Disease Assessment ◽

First Line ◽

Development And Validation ◽

LBA-04The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results

Annals of Oncology ◽

10.1093/annonc/mdw237.4 ◽

2016 ◽

Vol 27 (suppl_2) ◽

pp. ii141-ii141

Author(s):

J. Bennouna ◽

P.-L. Etienne ◽

E. Bogart ◽

M.-P. Galais ◽

M. Benabdelghani ◽

...

Keyword(s):

Quality Of Life ◽

Esophageal Cancer ◽

Squamous Cell ◽

First Line ◽

Line Chemotherapy ◽

Randomized Discontinuation Trial

Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost–utility analysis

Annals of Oncology ◽

10.1093/annonc/mdq431 ◽

2011 ◽

Vol 22 (3) ◽

pp. 567-574 ◽

Cited By ~ 12

Author(s):

M. Joerger ◽

K. Matter-Walstra ◽

M. Früh ◽

U. Kühnel ◽

T. Szucs ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cost Utility ◽

Small Cell ◽

Cost Utility Analysis ◽

Utility Analysis ◽

Small Cell Lung ◽

First Line ◽

LBA-04 The E-DIS study, a randomized discontinuation trial of first-line chemotherapy (CT) in patients with metastatic squamous-cell esophageal cancer (MSEC): efficacy and quality of life results

Annals of Oncology ◽

10.1093/annonc/mdw237.04 ◽

2016 ◽

Vol 27 ◽

pp. ii141

Author(s):

J. Bennouna ◽

P.-L. Etienne ◽

E. Bogart ◽

M.-P. Galais ◽

M. Benabdelghani ◽

...

Keyword(s):

Quality Of Life ◽

Esophageal Cancer ◽

Squamous Cell ◽

First Line ◽

Line Chemotherapy ◽

Randomized Discontinuation Trial

PCN115 COST UTILITY ANALYSIS OF 90Y-IBRITUMOMAB TIUXETAN FOLLOWING FIRST-LINE CHEMOTHERAPY COMPARED TO NO FOLLOW-UP IN PATIENTS WITH STAGE III OR IV FOLLICULAR LYMPHOMA IN SPAIN

Value in Health ◽

10.1016/s1098-3015(10)74366-7 ◽

2009 ◽

Vol 12 (7) ◽

pp. A279

Author(s):

SG Eggington ◽

C Piñol ◽

E Musi ◽

A Valderrama

Keyword(s):

Follicular Lymphoma ◽

Cost Utility ◽

Cost Utility Analysis ◽

Stage Iii ◽

Utility Analysis ◽

First Line ◽

Ibritumomab Tiuxetan ◽

Modified FLOX as first-line chemotherapy for metastatic colorectal cancer patients in the public health system in Brazil: Effectiveness and cost-utility analysis

Molecular and Clinical Oncology ◽

10.3892/mco.2012.12 ◽

2012 ◽

Vol 1 (1) ◽

pp. 175-179 ◽

Cited By ~ 9

Author(s):

DANIELA R. NEBULONI ◽

MILENA P. MAK ◽

FABIANO HAHN SOUZA ◽

DANIEL F. SARAGIOTTO ◽

THIAGO JÚLIO ◽

...

Keyword(s):

Public Health ◽

Colorectal Cancer ◽

Public Health System ◽

Cost Utility ◽

Cost Utility Analysis ◽

Utility Analysis ◽

First Line ◽

The Public ◽

Colorectal Cancer Patients ◽